Skip Navigation


NDT Advance Access originally published online on October 18, 2006
Nephrology Dialysis Transplantation 2007 22(1):15-20; doi:10.1093/ndt/gfl581
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/1/15    most recent
gfl581v3
gfl581v2
gfl581v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bakker, S. J. L.
Right arrow Articles by de Zeeuw, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bakker, S. J. L.
Right arrow Articles by de Zeeuw, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Metabolic syndrome: a fata morgana?

Stephan J. L. Bakker1, Ron T. Gansevoort1 and Dick de Zeeuw1,2

1Department of Internal Medicine and 2Department of Clinical Pharmacology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands

Correspondence and offprint requests to: Dr S. J. L. Bakker, Department of Internal Medicine, University Hospital Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands. Email: s.j.l.bakker@int.umcg.nl

Keywords: cardiovascular disease; dialysis; endstage renal disease; metabolic syndrome; obesity; renal insufficiency

The first 150 words of the full text of this article appear below.



   Metabolic syndrome: metabolic/medical complications of obesity
 
The criteria used to define the metabolic syndrome are increased waist circumference, increased triglycerides, decreased HDL-cholesterol, increased blood pressure and increased plasma glucose. According to the most widely used definition, the metabolic syndrome is diagnosed in persons who have three or more of these five abnormalities [1]. The history of the designation of the syndrome dates back to 1993, when it was stressed in the second report of the Adult Treatment Panel (ATP-II) of the National Cholesterol Education Program (NCEP), that the rising prevalence of obesity should be controlled from the perspective of prevention of cardiovascular (CV) disease [2]. Later, it was acknowledged that, despite recommendations, the problem of obesity had taken immense proportions, and that it would be a daunting task to treat every obese subject. In the third report of the Adult Treatment Panel (ATP-III) of the NCEP, in 2001, the metabolic syndrome was . . . [Full Text of this Article]



   Is the metabolic syndrome useful for assessment of cardiovascular or renal risk?
 


   Is the concept of the metabolic syndrome then worthless?
 


   What warnings does the obesity epidemic contain for kidneys and dialysis capacity?
 


   Medical complications of prolonged obesity
 


   Obesity-related renal disease
 


   Potential impact of an obesity paradox on incidence of ESRD
 


   Implications of the metabolic syndrome for the management of renal patients
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
E. Ritz
Metabolic Syndrome: An Emerging Threat to Renal Function
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 869 - 871.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Ar. Mani, J. Radhakrishnan, H. Wang, Al. Mani, M.A. Mani, C. Nelson-Williams, K.S. Carew, S. Mane, H. Najmabadi, D. Wu, et al.
Metabolic Syndrome--What We Know and What We Don't Know: LPR6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors. Science 315: 1278-1282, 2007
J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1619 - 1623.
[Full Text] [PDF]